-+ 0.00%
-+ 0.00%
-+ 0.00%

French Drugmaker Sanofi Wins EU Nod for Rabies Vaccine VaxRabeo

MT Newswires·11/19/2026 01:32:49
Listen to the news
01:32 AM EST, 11/19/2026 (MT Newswires) -- Sanofi (SAN.PA) secured the European Commission's marketing authorization for its rabies vaccine VaxRabeo, marking its first approval. The vaccine is approved for pre-exposure prophylaxis and post-exposure prophylaxis against rabies across all age groups, the French drugmaker said Thursday. Sanofi added that VaxRabeo has a longer shelf life than its current rabies vaccines. The approval follows a positive opinion from the European Medicines Agency's human medicines committee in September. It is backed by a comprehensive clinical program comparing VaxRabeo with Sanofi's existing rabies vaccines in both pre- and post-exposure settings, covering all age groups and World Health Organization-recommended vaccination schedules.